StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.82+0.24 (+9.30%)

Close on Nov 18, 2026Market cap $114.20MP/E –Yield –

OnKure Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

OnKure Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$62.14M. For fiscal 2025 it was -$62.95M. The highest annual figure on record is -$19.55M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$62.95M–
FY2024Dec 31, 2024-$54.39M–
FY2023Dec 31, 2023-$36.93M–
FY2022Dec 31, 2022-$53.85M–
FY2021Dec 31, 2021-$39.82M–
FY2020Dec 31, 2020-$19.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.90M–
Q1 FY2026Mar 31, 2026-$15.62M–
Q4 FY2025Dec 31, 2025-$14.13M–
Q3 FY2025Sep 30, 2025-$15.50M–
Q2 FY2025Jun 30, 2025-$16.32M–
Q1 FY2025Mar 31, 2025-$17.00M–
Q4 FY2024Dec 31, 2024-$18.70M-188.6%
Q3 FY2024Sep 30, 2024-$11.51M–
Q2 FY2024Jun 30, 2024-$14.34M–
Q1 FY2024Mar 31, 2024-$9.83M–
Q4 FY2023Dec 31, 2023$21.11M–
Q3 FY2023Sep 30, 2023-$20.89M–
Q2 FY2023Jun 30, 2023-$21.04M–
Q1 FY2023Mar 31, 2023-$16.12M–
Q4 FY2022Dec 31, 2022-$14.56M–
Q3 FY2022Sep 30, 2022-$13.84M–
Q2 FY2022Jun 30, 2022-$12.43M–
Q1 FY2022Mar 31, 2022-$13.02M–
Q4 FY2021Dec 31, 2021-$10.62M–
Q3 FY2021Sep 30, 2021-$12.75M–
Q2 FY2021Jun 30, 2021-$9.23M–
Q1 FY2021Mar 31, 2021-$7.21M–
Q4 FY2020Dec 31, 2020-$6.25M–
Q3 FY2020Sep 30, 2020-$5.10M–
Q2 FY2020Jun 30, 2020-$3.70M–
Q1 FY2020Mar 31, 2020-$4.50M–

More OnKure Therapeutics figures

See a number that looks wrong?